Articles from Nuclera

Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced a USD $12 million financing extension, bringing the Company’s total Series C funding to USD $87 million. The raise was led by Elevage Medical Technologies and Jonathan Milner, joined by existing investors British Business Bank and GK Goh. The investment will accelerate the integration of antibody expression and binding validation capabilities into the Company’s eProtein Discovery benchtop system, which enables multiplex protein screening, characterization, and expression in-house.

Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced that it has signed a partnership with Solve Scientific Australia, a life science research solutions provider. The agreement is the latest milestone in Nuclera’s global expansion, broadening access to eProtein Discovery to customers in Australia and New Zealand, and amplifying the Company’s presence in key Asian and Pacific markets.

Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a collaboration with Cytiva, a global life sciences leader. This collaboration is focused on accelerating the production, purification and characterization of proteins required for drug research and development, enabled through the combination of Nuclera’s eProtein Discovery System with Cytiva’s Biacore™ surface plasmon resonance (SPR) technology.

Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, today announced that it has established a distribution network across APAC and the Middle East. Marking a key milestone in the Company’s global commercial strategy, the expansion establishes new regional distribution networks, providing localized technical support for customers in these key markets.

Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the addition of a new membrane protein workflow to its system. This expanded capability enables the expression, purification and stabilization of challenging membrane proteins, which are often key targets in therapeutic development. Using cell-free protein synthesis, digital microfluidics, and optimized additive screening, eProtein Discovery can express and purify functional, correctly folded membrane proteins, in 48 hours.

Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced that it has appointed Seth Benson as Chief Financial Officer. Seth joins CEO, Dr Michael Chen, on the executive team to advance commercial and strategic initiatives, drive revenue and support expansion of the business following the close of the Company’s USD $75 million financing round1.

Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the appointment of William J. Kullback to its Board of Directors as a Non-Executive Director (NED).

Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, and Domainex, a multi-award winning provider of integrated, pre-clinical drug discovery services, today announced that Domainex is the first contract research organization (CRO) to have installed the eProtein Discovery system and offer protein production services using the technology.

Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, today announced it has completed a USD $75 million financing round (circa £57 million). The fundraise was led by Elevage Medical Technologies, backed by Patient Square Capital, and joined by British Patient Capital, the largest domestic investor in UK venture and venture growth opportunities, Cambridge Innovation Capital, Jonathan Milner, GK Goh, M&G Catalyst, E Ink Holdings, Michael D. McCreary, Uni Power Group, and Verve Ventures. Taylor Wessing advised Nuclera on the transaction. The investment will enable the continued commercialization of Nuclera’s eProtein Discovery™ benchtop system, particularly in the US and across Europe.

Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop eProtein Discovery™ system, today announced it has been awarded two highly competitive Innovate UK grants totaling £1.14M. The funding, made up of a £790k flexible, agile, scalable, and sustainable technologies (FASST) grant awarded in collaboration with DeepMirror, and a £350k Engineering Biology grant, to further develop the platform, including evaluations by Dr Konstantinos Beis, an independent expert from Imperial College London, and Dr Andrew Quigley from Diamond Light Source.

Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, today announced it has successfully completed 11 installs of its eProtein Discovery™ system, including at leading academic institutes. Following the first launch installation at the University of Southampton1, the system has been placed in academic institutions including, University College London, University of Cambridge, University of Manchester, The Flanders Institute for Biotechnology (VIB) in Belgium, and the CRUK Cambridge Institute.

Nuclera, a UK-based biotech company developing cutting-edge benchtop protein printing technologies, announces the opening of its US subsidiary in Boston, MA.